Overview

Cinsulin is a branded, water-extracted cinnamon preparation developed and patented to deliver a standardized concentration of type-A doubly linked procyanidin polymers, which are believed to be the primary bioactive compounds responsible for cinnamon's metabolic effects. The extraction process uses water rather than organic solvents, which selectively concentrates the hydrophilic polyphenol fraction while significantly reducing the levels of lipophilic coumarin and cinnamaldehyde found in whole cinnamon bark.

The type-A procyanidins in Cinsulin have been shown in vitro to mimic insulin signaling by activating insulin receptor autophosphorylation and downstream kinase cascades, promoting glucose uptake in adipocytes and muscle cells. This mechanism distinguishes the water-soluble cinnamon fraction from the volatile oil components, which act through different pathways. By standardizing the extract to these specific polymers, Cinsulin aims to provide more consistent and reproducible metabolic effects compared to non-standardized cinnamon supplements.

Clinical studies using the water-soluble cinnamon extract technology behind Cinsulin have demonstrated reductions in fasting blood glucose in individuals with prediabetes and type 2 diabetes, with some trials also reporting improvements in systolic blood pressure and body composition. The reduced coumarin content addresses a key safety concern associated with long-term Cassia cinnamon supplementation, as the European Food Safety Authority has established a tolerable daily intake for coumarin of 0.1 mg per kilogram of body weight. Cinsulin is typically dosed at 250-500 mg per day and is marketed both as a standalone supplement and as an ingredient in multi-component metabolic support formulations.

Mechanism of Action

Water-Extracted Cinnamon — Polyphenol Type A Concentrate

Cinsulin (Cinnulin PF) is a patented water-extract of Cinnamomum burmannii bark that concentrates type A doubly-linked procyanidin polymers while removing lipophilic coumarins (particularly coumarin itself, a hepatotoxin present at 2,000-5,000 ppm in whole cassia cinnamon bark). The aqueous extraction process enriches the procyanidin trimer-to-pentamer fraction approximately 20-fold compared to crude bark powder, standardized to contain a minimum 3% type A polymers. This addresses the safety concern of chronic coumarin exposure from whole cinnamon supplementation, which can exceed the European Food Safety Authority's tolerable daily intake of 0.1 mg/kg body weight (PMID: 20536390).

Insulin Receptor Potentiation & PTP1B Inhibition

The concentrated type A procyanidins in Cinsulin activate insulin receptor beta-subunit autophosphorylation with greater potency than equivalent doses of crude cinnamon extract. They simultaneously inhibit protein tyrosine phosphatase 1B (PTP1B) — the primary negative regulator that dephosphorylates the insulin receptor and IRS-1 — prolonging the duration of insulin signaling. This dual mechanism (receptor activation + phosphatase inhibition) produces synergistic enhancement of IRS-1/PI3K/Akt pathway activity, GLUT4 translocation, and glucose uptake in skeletal muscle and adipose tissue (PMID: 19930003).

Clinical Glycemic & Body Composition Effects

Randomized controlled trials with Cinsulin (500 mg/day, equivalent to 10 g crude cinnamon) demonstrate significant reductions in fasting blood glucose (8-15%), improvements in body composition (reduced body fat percentage), and enhanced lean mass in subjects with metabolic syndrome. The extract also reduces systolic blood pressure by 3-5 mmHg, potentially through enhanced endothelial nitric oxide synthase (eNOS) coupling via Akt-mediated phosphorylation at Ser1177 (PMID: 16634838).

Antioxidant & AGE Inhibition

Cinsulin's procyanidin fraction scavenges reactive oxygen species and inhibits methylglyoxal-mediated protein glycation, reducing advanced glycation end-product (AGE) formation that drives diabetic microvascular complications including nephropathy and retinopathy (PMID: 22327862).

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Cinsulin (Cinnulin PF / Type-A Polymers)

Common Side Effects

• Mild gastrointestinal discomfort: bloating, nausea, and stomach upset during the first week of use
• Slight metallic or cinnamon aftertaste
• Mild headache, particularly when initiating supplementation
• Rare skin flushing or warmth sensation

Serious Adverse Effects

• Hypoglycemia: as a concentrated cinnamon extract standardized to type-A polymers, Cinsulin can potentiate insulin sensitivity; when combined with diabetes medication, symptomatic hypoglycemia (blood glucose <70 mg/dL) is a real risk
• Liver effects: while Cinsulin (Cinnulin PF) is specifically processed to remove most coumarin (>95% reduction vs. crude Cassia bark), residual traces may still pose concerns in individuals with hepatic impairment
• Allergic reactions: cinnamon sensitivity or cinnamaldehyde allergy may still be triggered despite processing; reactions range from urticaria to rare anaphylaxis
• Theoretical risk of excessive platelet inhibition when combined with anticoagulants (less than crude cinnamon but not zero)

Contraindications

• Known allergy to cinnamon, cinnamaldehyde, or cinnamon-derived products
• Active hepatic disease, especially coumarin-sensitive liver injury
• Uncontrolled hypoglycemia or insulinoma
• Do not use as a replacement for prescribed antidiabetic medications

Drug Interactions

• Insulin and oral hypoglycemics (metformin, glipizide, pioglitazone): potentiated glucose-lowering; requires blood glucose monitoring and potential medication dose reduction
• Anticoagulants: while coumarin is largely removed, residual amounts plus polyphenol-mediated platelet inhibition warrant caution with warfarin or DOACs
• CYP3A4 and CYP2E1 substrates: cinnamon polyphenols may modestly inhibit these enzymes; monitor drugs with narrow therapeutic windows (cyclosporine, certain statins)
• Alpha-lipoic acid and berberine: stacking multiple insulin-sensitizing supplements compounds hypoglycemia risk
• Chromium picolinate: frequently co-administered for glucose control but additive hypoglycemia potential

Population-Specific Considerations

• Type 2 diabetes: primary target population; clinical trials show fasting glucose reductions of 8–18 mg/dL at 500 mg/day; always use under medical supervision alongside standard therapy
• Pregnancy / lactation: insufficient safety data for concentrated extract; avoid or use only under provider guidance
• Children and adolescents: no pediatric dosing data; not recommended
• Elderly: heightened hypoglycemia vulnerability; start at lowest dose (250 mg/day) and titrate
• Metabolic syndrome (non-diabetic): generally well-tolerated at standard doses (500 mg/day); monitor fasting glucose periodically
• Hepatic impairment: despite reduced coumarin content, use with caution and monitor liver function tests quarterly

Pharmacokinetic Profile